Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chromadex (CDXC)
NASDAQ:CDXC
Holding CDXC?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.02Last Year’s EPS
$0Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: 57.31%
|Next Earnings Date:Mar 05, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant positive financial performance, with record revenue and growth primarily driven by NIAGEN and e-commerce sales. The company also made strategic advancements with the NIAGEN+ product line and FDA communications. However, challenges in the Hong Kong market and increased legal expenses were noted as lowlights.Company Guidance
In the third quarter of 2024, ChromaDex reported record financial results, with revenue reaching $25.6 million, a 31% increase year-over-year, and net income of $1.9 million. The quarter marked the sixth consecutive period of positive adjusted EBITDA at $2.9 million and generated a total positive cash flow of $5.1 million. The company ended the quarter with $32.4 million in cash and no debt. This financial performance was driven by a significant 368% increase in NIAGEN ingredient sales, totaling $14.8 million, and a 16% growth in e-commerce sales. The gross margin improved to 63.5%, up from 61.4% in the same quarter of the previous year, highlighting effective fiscal discipline and cost management. The company anticipates approximately 15% year-over-year growth for the full year 2024, primarily led by its global e-commerce business and the launch of NIAGEN IV.Record Revenue and Positive Growth
ChromaDex achieved record results with $25.6 million in revenue, marking a 31% increase year-over-year. The company also reported net income of $1.9 million and a sixth consecutive quarter of positive adjusted EBITDA at $2.9 million.
Strong E-commerce and NIAGEN Sales
Growth was driven by e-commerce and NIAGEN ingredient sales, with a 368% increase in NIAGEN ingredient sales. E-commerce sales saw a 16% growth year-over-year.
Improved Financial Position
The company generated positive cash flow of $5.1 million, ending the quarter with $32.4 million in cash and no debt. Gross margins improved to 63.5%, up from 61.4% in the prior year.
NIAGEN+ Product Line Expansion
The NIAGEN+ product line, including NIAGEN IV and injections, was launched in over 100 clinics and is expected to reach over 300 clinics soon.
FDA Communication and AT Treatment Development
ChromaDex initiated communication with the FDA for an investigational new drug application for the use of NR in the treatment of ataxia telangiectasia.
---
CDXC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CDXC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $3.49 | $5.86 | +67.91% |
| Aug 07, 2024 | $2.63 | $2.88 | +9.51% |
| May 08, 2024 | $3.83 | $3.52 | -8.09% |
| Mar 06, 2024 | $1.74 | $1.60 | -8.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Chromadex (CDXC) report earnings?
Chromadex (CDXC) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Chromadex (CDXC) earnings time?
Chromadex (CDXC) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDXC EPS forecast?
CDXC EPS forecast for the fiscal quarter 2024 (Q4) is $0.02.
---